24 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
company, as applicable. These exemptions include reduced disclosure obligations regarding executive compensation and only two years of audited
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
company, as applicable. These exemptions include reduced disclosure obligations regarding executive compensation and only two years of audited
S-3ASR
ymmpv46h6s 046r5np
23 Sep 22
Automatic shelf registration
4:08pm
424B5
lg44ja6 6y2ce
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
6z383lrp2cpawkkhjj
20 Jul 22
Prospectus supplement for primary offering
4:22pm
S-3
3a3wf7xnssznj hzjuwf
1 Jul 22
Shelf registration
4:36pm
DEF 14A
awah4nklw0e 8v
29 Apr 22
Definitive proxy
7:01am
10-K
bbiitru1nn f8
14 Mar 22
Annual report
7:04am
10-Q
52ptx0eh9z
12 Aug 21
Quarterly report
8:53am